Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1 along with related funding status notices; these are system-level updates that do not alter study details.SummaryDifference0.4%

- Check8 days agoChange DetectedAdded a site-wide notice about government funding status and updated the platform version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check15 days agoChange DetectedThese updates include additions of a glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, and deletions of the prior variants Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check29 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. This is a minor technical update and does not affect any study details or data.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page updated its Locations section to add sites across multiple states including Colorado, District of Columbia, Louisiana, Maryland, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, and Washington, and removed the previous state locations; the revision tag also updated to v3.3.3.SummaryDifference1%

- Check79 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2, indicating a minor update to the study record. This change does not modify the study details or enrollment information.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.